ECX.F · Epigenomics AG

-

Please sign in to comment on ECX.F

1 Comment

Admin

4 years, 10 months ago

Epigenomics AG is currently in a long term downtrend where the price is trading 35.1% below its 200 day moving average.

From a valuation standpoint, the stock is 98.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 15.5.

Epigenomics AG's total revenue rose by 8.3% to $301K since the same quarter in the previous year.

Its net income has increased by 63.2% to $-3M since the same quarter in the previous year.

Finally, its free cash flow grew by 22.4% to $-2M since the same quarter in the previous year.

Based on the above factors, Epigenomics AG gets an overall score of 4/5.

CurrencyCode	EUR
Exchange	F
ISIN	DE000A37FT41
Sector	Healthcare
Industry	Diagnostics & Research

Beta	0.82
Target Price	5.32
Market Cap	782K
PE Ratio	None
Dividend Yield	None

ABOUT

Epigenomics AG

Epigenomics AG does not have significant operations. Previously, the company was involved in liquid biopsy for the early detection of cancer. The company was founded in 1998 and is headquartered in Heidelberg, Germany.

ECX.F · Epigenomics AG

-

Epigenomics AG

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Epigenomics AG using a moving average strategy